

Wyoming Drug Utilization Review
P & T Committee Meeting
November 13, 2025
Cheyenne, Wyoming
10 am - 1 pm

AGENDA

- I. Introduction and Announcements
- II. Approval of minutes of August 14, 2025
- III. Department of Health
 - A. Pharmacy Program Manager Report
 - B. Medical Director Report
 - C. DUR Manager Report
- IV. Old Business
 - A.
- V. New Business
 - A. PA Criteria
 - 1. Review existing PA criteria
 - i. Ajoyv for 6 – 12 years
 - ii. Wegovy for MASH
 - iii. Mavaret for acute Hep C infection
 - iv. Qulipta with Botox
 - v. Zoryve for pediatric dermatitis (2 – 5)
 - vi. CGMs for gestational diabetes
 - 2. New Drugs
 - i. Tryptyr
 - ii. Harliku
 - iii. Ekterly
 - iv. Orlynvah
 - v. Anzupgo
 - vi. Sephience
 - vii. Vizz
 - viii. Brinsupri
 - ix. Dawnzera
 - x. Wayrilz
 - xi. Exxua
 - xii. Palsonify
 - xiii. Forzinity
 - xiv. Rhapsido
 - 3. Determine need for criteria
 - i. Leucovorin for autism
 - 4. Physician Administered Drugs
 - i. Papzimeos
- VI. Other
 - A.
- VII. Open Comments

The business portion of the meeting will be from 10 am to approximately 11:30 am. (Agenda items I - VI). The executive session (item VII) begins at approximately 11:45 am. Committee members who are unable to attend please inform Aimee at alewis13@uwyo.edu or 307-766-6750.